Latest News

Four of the chipmaker's five previous best years since 1981 were followed by a down year. Why would 2027 be different?

The industry disruptor hasn't been a market-beating investment for its shareholders.

SpaceX is currently valued at roughly $2 trillion.

Palantir's growth is extraordinary, but the valuation sets a demanding bar. See what AIP, margins, government demand, and the math reveal about its long-term upside.

Nkarta (NASDAQ:NKTX) said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology’s 2026 Convergence meeting in November, including presentations in myositis, scleroderma and program-wide safety. The company is developing an allogenei

Managing investments may not quite be the business you think it is.

The U.S. government is taking active equity stakes in businesses and is directly shaping capital allocation decisions.

Ford's revenue remains roughly double Tesla's, yet the gap has narrowed noticeably over eight quarters as Tesla's growth accelerates.

Rushing into things is a mistake you might regret.

Investors always need to balance risk versus reward, with industry watchers increasingly warning about risk right now.

A record number of people have become millionaires by contributing to an IRA. Here's how.

A wave of AI leaders are warning about the pace of frontier models and their fear of them getting “out of control.” However, there may be other reasons why they’re sounding the alarm at this precise moment.

Once a high-flying stock posting huge returns, this premium apparel brand has fallen out of favor.

PRA Group (NASDAQ:PRAA) outlined its strategy, operating trends and capital priorities during a company presentation, highlighting a favorable supply environment for non-performing loan portfolios, ongoing cost reductions and investments in technology. Chief Executive Officer Martin Sjolund said th

Nearly annual COLAs can help retirees keep up with inflation, but they're often not enough.

Value investors might lean toward the apparel stock, but that's a risky proposition.

The warehouse club operator is a bargain, even if its price tag and valuation might seem high.

Use patience and fundamentals to navigate volatile IPOs.

Who doesn't want some extra passive income?

A 13.6% plunge in SpaceX tests investor risk, volatility, and earnings expectations.

AI could drive SpaceX's growth. It's also driving up costs.

Palisade Bio (NASDAQ:PALI) said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn’s disease after completing its Phase I program. Chief Executive Officer JD Finley said PALI-2108 is a once-daily oral phosphodiesterase 4, or PDE4, inhibitor de

The exuberance surrounding Intel's stock is getting a bit too high.

This biotech has grabbed plenty of headlines recently.

Lululemon faces mounting governance risks as investors question leadership credibility.